In this Issue:
Reduced-intensity chemotherapy plus imatinib in Ph+ ALL
Daunorubicin 90 vs. 60 mg/m2 in AML induction
SNPs of cytarabine metabolism-related genes in AML
Lower dose prednisone for initial GVHD treatment
Health-related QOL with lenalidomide + low-dose dexamethasone in new MM
Mutations and long-term ET/early primary myelofibrosis outcomes
Ruxolitinib in myelofibrosis
ABVD vs. Stanford V in stage I/II bulky mediastinal HL
HL risk following infectious and chronic inflammatory diseases
Please login below to download this issue (PDF)